Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Elevance Health Inc (NYSE: ELV) closed at $313.19 in the last session, down -1.26% from day before closing price of $317.2. In other words, the price has decreased by -$1.26 from its previous closing price. On the day, 1.53 million shares were traded. ELV stock price reached its highest trading level at $318.5 during the session, while it also had its lowest trading level at $308.8282.
Ratios:
We take a closer look at ELV’s different ratios to gain a better understanding of the stock. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.71.
Leerink Partners Downgraded its Outperform to Market Perform on July 18, 2025, while the target price for the stock was maintained at $310.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when DeVore Susan D. bought 1,200 shares for $312.15 per share. The transaction valued at 374,580 led to the insider holds 3,502 shares of the business.
BOUDREAUX GAIL bought 8,500 shares of ELV for $2,438,951 on Jul 18 ’25. The President and CEO now owns 151,020 shares after completing the transaction at $286.94 per share. On Apr 24 ’25, another insider, Kaye Mark, who serves as the EVP & CFO of the company, sold 4,588 shares for $424.82 each. As a result, the insider received 1,949,074 and left with 18,977 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELV now has a Market Capitalization of 69602959360 and an Enterprise Value of 65617956864. As of this moment, Elevance’s Price-to-Earnings (P/E) ratio for their current fiscal year is 12.81, and their Forward P/E ratio for the next fiscal year is 11.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.36 while its Price-to-Book (P/B) ratio in mrq is 1.58. Its current Enterprise Value per Revenue stands at 0.337 whereas that against EBITDA is 7.353.
Stock Price History:
The Beta on a monthly basis for ELV is 0.60, which has changed by -0.24073052 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, ELV has reached a high of $458.75, while it has fallen to a 52-week low of $273.71. The 50-Day Moving Average of the stock is -4.79%, while the 200-Day Moving Average is calculated to be -14.62%.
Shares Statistics:
According to the various share statistics, ELV traded on average about 2.04M shares per day over the past 3-months and 2028000 shares per day over the past 10 days. A total of 222.04M shares are outstanding, with a floating share count of 221.71M. Insiders hold about 0.24% of the company’s shares, while institutions hold 93.84% stake in the company. Shares short for ELV as of 1760486400 were 2731969 with a Short Ratio of 1.34, compared to 1757894400 on 3677507. Therefore, it implies a Short% of Shares Outstanding of 2731969 and a Short% of Float of 1.23000005.
Dividends & Splits
The forward annual dividend rate for ELV is 6.76, which was 6.76 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.021311475. The stock’s 5-year Average Dividend Yield is 1.26. The current Payout Ratio is 25.39% for ELV, which recently paid a dividend on 2025-09-10 with an ex-dividend date of 2025-12-05. Stock splits for the company last occurred on 2005-06-01 when the company split stock in a 2:1 ratio.
Earnings Estimates
The dynamic stock of Elevance Health Inc (ELV) is currently attracting attention from 20.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $10.86, with high estimates of $13.99 and low estimates of $7.57.
Analysts are recommending an EPS of between $30.17 and $29.67 for the fiscal current year, implying an average EPS of $29.97. EPS for the following year is $27.64, with 22.0 analysts recommending between $34.0 and $24.5.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $49.63B. It ranges from a high estimate of $51.04B to a low estimate of $48.4B. As of. The current estimate, Elevance Health Inc’s year-ago sales were $44.99BFor the next quarter, 11 analysts are estimating revenue of $50.83B. There is a high estimate of $51.84B for the next quarter, whereas the lowest estimate is $49.27B.
A total of 13 analysts have provided revenue estimates for ELV’s current fiscal year. The highest revenue estimate was $201.01B, while the lowest revenue estimate was $196.67B, resulting in an average revenue estimate of $197.93B. In the same quarter a year ago, actual revenue was $175.2BBased on 12 analysts’ estimates, the company’s revenue will be $204.99B in the next fiscal year. The high estimate is $213.85B and the low estimate is $197.52B.
